Effects of thyroid hormone on the renal dopaminergic system.
This study determined the effects of thyroid hormone on the renal dopaminergic system. Surgical thyroidectomy (Tx) and treatment with 2-thiouracil (Thio) decreased renal cortex Na+/K+ ATPase activity and urinary volume. Tx also decreased urinary Na+ and urinary L-DOPA without changing urinary excretion of Dopamine (DA). Thio treatment decreased slightly urinary L-DOPA and Na+, but increased urinary excretion of DA. In both models of thyroid hormone deficiency, the ratio urinary DA/DOPA increased. Changes after Thio treatment were reversed after one month of drug withdrawal. Treatment with T3 via osmotic minipump increased Na+/K+ ATPase activity and urinary L-DOPA, did not change urinary DA, and increased the ratio DA/DOPA. To further analyze the effects of thyroid hormone deficiency, we administered selective DA1 (SCH-23390), DA2 (Sulpiride), and a non selective (Haloperidol) DA receptor antagonists to Thio treated and control animals. The DA1 antagonist decreased diuresis, natriuresis and urinary L-DOPA in control, but had no effect in Thio treated rats. Sulpiride had no effect in either group. The combination of SCH-23390 plus Sulpiride decreased urinary L-DOPA and urinary volume only in Thio treated animals. Haloperidol decreased urinary volume in Thio treated animals, but had no effect in controls. Our findings suggest that renal DA synthesis is to some extent dependent on thyroid hormone levels, and that the response of DA receptors is altered by thyroid hormone deficiency, indicating a role of this hormone in the regulation of the renal dopaminergic system.
Del Compare
J A
JA
Centro de Investigaciones Endocrinologicas, CONICET, Buenos Aires, Argentina. cedie@pccp.com.ar
Aguirre
J A
JA
Ibarra
F R
FR
Barontini
M
M
Armando
I
I
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism / Q000652:urine; D000818:Animals; D013956:Antithyroid Agents / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D002396:Catechols / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000378:metabolism / Q000652:urine; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006980:Hyperthyroidism / Q000378:metabolism; D007037:Hypothyroidism / Q000378:metabolism; D007668:Kidney / Q000187:drug effects*; D008297:Male; D051381:Rats; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013889:Thiouracil / Q000494:pharmacology; D013963:Thyroid Hormones / Q000097:blood / Q000494:pharmacology*; D013965:Thyroidectomy
D013956:Antithyroid Agents; D001552:Benzazepines; D002396:Catechols; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; D013963:Thyroid Hormones; D015102:3,4-Dihydroxyphenylacetic Acid; D013889:Thiouracil; D004295:Dihydroxyphenylalanine; D000254:Sodium-Potassium-Exchanging ATPase; D006220:Haloperidol; D004298:Dopamine